Market Overview

UPDATE: Dawson James Initiates Galena Biopharma at Market Outperform

Related GALE
Markets Continue To Rally Ahead Of Yellen's Speech At Jackson Hole
Galena Biopharma Appoints Mark W. Schwartz, Ph.D., As President And CEO

Dawson James initiated coverage on Galena Biopharma (NASDAQ: GALE) with a Buy rating and a $3 price target.

Dawson James commented, "We believe investors have yet to fully appreciate NeuVax's clinical potential and chance of success in the Phase III PRESENT study currently underway. After assessing the NeuVax Phase II data on hand and speaking with Company management, we believe Galena has managed to implement several key insights gained from prior trials into in the Phase III PRESENT study, ignificantly improving its likelihood of success."

Galena Biopharma closed at $1.68 on Monday.

Posted-In: Dawson James iAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GALE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional